Berger Montague Announces Class Action Lawsuit Against Tenax Therapeutics Following Phase 3 Trial Failure
Law firm Berger Montague has filed a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) on behalf of investors who purchased securities between November 13, 2023, and August 7, 2026. The lawsuit alleges that the company and its officers misrepresented the development prospects of TNX-103, an oral levosimendan candidate intended for pulmonary hypertension treatment. The legal action follows a significant market event on August 10, 2026, when Tenax announced that its Phase 3 LEVEL trial failed to meet both its primary endpoint and key secondary endpoints. This clinical failure resulted in a massive single-day stock price collapse of approximately 89.77%, dropping the share price to $1.38. Investors seeking lead plaintiff status have until December 28, 2026, to apply.
Tickers: $TENX
Topics: clinical trial failure investor lawsuit securities litigation
Read the full article at PR Newswire
Part of the story Bronstein Gewirtz & Grossman Announces Class Action Lawsuit Against Tenax Therapeutics (TENX) (3 articles)